EGFR L858R

Clinical trials for EGFR L858R explained in plain language.

Never miss a new study

Get alerted when new EGFR L858R trials appear

Sign up with your email to follow new studies for EGFR L858R, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Completed 1

Double-Dose drug combo tested to fight tough lung cancer mutation

Disease control Completed

This study tested a combination of two drugs, bevacizumab and a double dose of icotinib, as a first treatment for people with advanced non-squamous non-small cell lung cancer (NSCLC) who have a specific genetic change called an EGFR L858R mutation. The main goal was to see if thi…

Matched conditions: EGFR L858R

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated Mar 16, 2026 15:25 UTC

EGFR L858R

Get alerted when new EGFR L858R trials appear

Double-Dose drug combo tested to fight tough lung cancer mutation